Home/Biosimilar Atlas/Companies/Marvel Lifesciences

Marvel Lifesciences

Biosimilar developer, United Kingdom. 1 development product across 1 molecule: insulin human.

FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product0 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Insulin humanSolumarv·withdrawn·····0/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Marvel Lifesciences, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

BaxterOne shared molecule: insulin human2 molecules in its portfolioBiocon BiologicsOne shared molecule: insulin human9 molecules in its portfolioCadila PharmaceuticalsOne shared molecule: insulin human2 molecules in its portfolioEpygen BiotechOne shared molecule: insulin human1 molecule in its portfolioEris LifesciencesOne shared molecule: insulin human2 molecules in its portfolioGland PharmaOne shared molecule: insulin human1 molecule in its portfolio

Chronology

Compare Marvel Lifesciences with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.